All In Biotech

Drug Trial Radar · NCT00115570

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Efficacy and Safety of Insulin Glulisine Compared With Insulin Lispro in Children and Adolescents With Type 1 Diabetes Mellitus: A 26 Week, Multicenter, Open, Parallel Clinical Trial

Last checked: Nov 20, 2026Latest source record: May 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 572 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

572

Actual

Start

Apr 2005

Primary completion

Nov 2006

Study completion Nov 2006

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 24, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 4 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Insulin-Dependent

Interventions

  • Insulin glulisineDrug

    Subcutaneous injection

  • insulin lisproDrug

    Subcutaneous injection

  • insulin glargineDrug

    Subcutaneous injection once daily

  • NPH insulinDrug

    subcutaneous injection twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in total glycated hemoglobin measured as HbA1c equivalents (GHb )from baseline to endpointTime frame: week 26 or last observed treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Childrens Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.